Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival - Results from the do tirofiban and ReoPro give similar efficacy outcome trial (TARGET)

被引:83
作者
Chan, AW
Moliterno, DJ
Berger, PB
Stone, GW
DiBattiste, PM
Yakubov, SL
Sapp, SK
Wolski, K
Bhatt, DL
Topol, EJ
机构
[1] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA
[2] Alton Ochsner Med Fdn & Ochsner Clin, Dept Cardiol, New Orleans, LA 70121 USA
[3] Mayo Clin & Mayo Fdn, Div Cardiol, Rochdale, MN USA
[4] Lenox Hill Heart & Vasc Inst, New York, NY USA
[5] Merck, W Point, PA USA
[6] Riverside Methodist Hosp, Columbus, OH 43214 USA
[7] Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA
关键词
D O I
10.1016/S0735-1097(03)00944-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to examine if clopidogrel treatment initiated before coronary stenting improved clinical outcomes among patients receiving aspirin and a glycoprotein (GP) IIb/IIIa inhibitor. BACKGROUND Antiplatelet therapy plays a pivotal role in contemporary percutaneous coronary interventions (PCI). METHODS Outcomes among 4,809 patients randomized to tirofiban or abciximab during PCI with stent placement were compared according to whether they received 300 mg of clopidogrel before PCI (93.1%) versus immediately after the procedure. RESULTS The 30-day primary composite end point (death, myocardial infarction [MI], or urgent target vessel revascularization [TVR]) was lower among clopidogrel-pretreated patients (6.6% vs. 10.4%, p = 0.009), mainly because of reduction of MI (6.0% vs. 9.5%, p = 0.012). The benefit of clopidogrel pretreatment was sustained at six months (death, MI, any TVR: 14.6% vs. 19.8%, HR = 0.71, p = 0.010), and this was due mainly to lowering of death and MI (7.8% vs. 13.0%, p = 0.001). At one year, clopidogrel pretreatment was associated with a lower mortality rate (1.7% vs. 3.6%, p = 0.011). Because clopidogrel pretreatment was not randomized, multivariable and propensity analyses were performed. After adjusting for baseline heterogeneity, clopidogrel pretreatment was an independent predictor for death or MI at 30 days (HR = 0.63, p = 0.012) and at six months (HR = 0.61, p = 0.003), and survival at one year (HR = 0.53, p = 0.044). No excess in 30-day bleeding events was noted with clopidogrel pretreatment. CONCLUSIONS Among patients undergoing coronary stent placement with aspirin and a GP IIb/IIIa inhibitor, clopidogrel pretreatment is associated with a reduction of death and MI irrespective of the type of GP IIb/IIIa inhibitor used. (C) 2003 by the American College of Cardiology Foundation.
引用
收藏
页码:1188 / 1195
页数:8
相关论文
共 49 条
[21]   Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors [J].
Lincoff, AM ;
Califf, RM ;
Moliterno, DJ ;
Ellis, SG ;
Ducas, J ;
Kramer, JH ;
Kleiman, NS ;
Cohen, EA ;
Booth, JE ;
Sapp, SK ;
Cabot, CF ;
Topol, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (05) :319-327
[22]   Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study [J].
Mehta, SR ;
Yusuf, S ;
Peters, RJG ;
Bertrand, ME ;
Lewis, BS ;
Natarajan, MK ;
Maimberg, K ;
Rupprecht, HJ ;
Zhao, F ;
Chrolavicius, S ;
Copland, I ;
Fox, KAA .
LANCET, 2001, 358 (9281) :527-533
[23]   A direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation and stent placement: Rationale and design of the TARGET study [J].
Moliterno, DJ ;
Topol, EJ .
AMERICAN HEART JOURNAL, 2000, 140 (05) :722-726
[24]   Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation [J].
Moussa, I ;
Oetgen, M ;
Roubin, G ;
Colombo, A ;
Wang, XD ;
Iyer, S ;
Maida, R ;
Collins, M ;
Kreps, E ;
Moses, JW .
CIRCULATION, 1999, 99 (18) :2364-2366
[25]   Platelet glycoprotein IIb/IIIa inhibitors - Recognition of a two-edged sword? [J].
Quinn, MJ ;
Plow, EF ;
Topol, EJ .
CIRCULATION, 2002, 106 (03) :379-385
[26]  
RAO AK, 1988, J AM COLL CARDIOL, V11, P1
[27]   Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation [J].
Rupprecht, HJ ;
Darius, H ;
Borkowski, U ;
Voigtländer, T ;
Nowak, B ;
Genth, S ;
Meyer, J .
CIRCULATION, 1998, 97 (11) :1046-1052
[28]   EFFECT OF THROMBOXANE A(2) BLOCKADE ON CLINICAL OUTCOME AND RESTENOSIS AFTER SUCCESSFUL CORONARY ANGIOPLASTY - MULTIHOSPITAL EASTERN ATLANTIC RESTENOSIS TRIAL (M-HEART-II) [J].
SAVAGE, MP ;
GOLDBERG, S ;
BOVE, AA ;
DEUTSCH, E ;
VETROVEC, G ;
MACDONALD, RG ;
BASS, T ;
MARGOLIS, JR ;
WHITWORTH, HB ;
TAUSSIG, A ;
HIRSHFELD, JW ;
COWLEY, M ;
HILL, JA ;
MARKS, RG ;
FISCHMAN, DL ;
HANDBERG, E ;
HERRMANN, H ;
PEPINE, CJ .
CIRCULATION, 1995, 92 (11) :3194-3200
[29]  
Savcic M, 1999, SEMIN THROMB HEMOST, V25, P15
[30]   A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [J].
Schomig, A ;
Neumann, FJ ;
Kastrati, A ;
Schuhlen, H ;
Blasini, R ;
Hadamitzky, M ;
Walter, H ;
ZitzmannRoth, EM ;
Richardt, G ;
Alt, E ;
Schmitt, C ;
Ulm, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (17) :1084-1089